B+
Bull case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-07-27 · RankAlpha Sentiment Codex
AGMB
AgomAb TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Agomab has multiple H2 2026 clinical milestones, recent FDA study-design alignment, and reported cash plus IPO proceeds expected to extend runway into the first half of 2029. [#IR-2026-06-23] [#PR-EARNINGS-2026-04-24]
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -5.7.
What can break
Binary clinical readout risk for ontunisertib and AGMB-447.
Momentum
70
Value
46
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.50 · Bull $24.00 · Bear $6.50Analysis 2026-07-27; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-27 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $37.14
Why
Momentum70 · Δ7d +25.3
Value46 · Δ7d 0.0
Sentiment52 · Δ7d -5.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -5.7.
Contradictions & invalidation
- • Binary clinical readout risk for ontunisertib and AGMB-447.
- • Clinical development cash burn and future dilution remain risks despite reported runway.
- • The thesis remains dependent on binary clinical execution.
Catalyst clock
2026-10-25
NOV-ERA Phase 2b initiation
Lead driver: Sentiment · See AI snapshot
Momentum
70
9% active weight
Current posture
7d trendImproving
Δ7d
+25.3
Δ21d
+13.2
Value
46
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.0
Sentiment
52
62% active weight
Current posture
7d trendSoftening
Δ7d
-5.7
Δ21d
+2.6
Why this grade
Composite grade D. Momentum 69.7 / Value 46.5 / Sentiment 52.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-27. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-07-27 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-07-27 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$673.71M
Beta
-
Shares Out
49.25M
P/E (TTM) · Derived
-9.4
P/S (TTM)
-
P/FCF (TTM)
-
Rev YoY
-
EPS YoY
+61.8%
Gross Margin
-
Op Margin
-
Net Debt
-$135.37M
Current Ratio
12.88
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data